You Have Great Science. Now Build the Plan That Gets It to the Clinic.
The Preclinical Roadmap is a diligence-ready development plan from discovery through IND-enabling. Start with a Strategy Diagnostic to identify your critical gaps, then build the plan that survives investor scrutiny and regulatory expectations.
Complimentary. 30 minutes. No obligation.
Before You Commit $200K+ to Your Next CRO Study
Most preclinical failures aren't caused by bad science. They're caused by running the wrong study first, using the wrong model, or spending 6 months on work that doesn't answer the question investors actually care about.
The Preclinical Roadmap gives you a diligence-ready development plan that catches these mistakes before they cost you runway and credibility. Start with a Strategy Diagnostic to identify the gaps, then build the plan that gets your program to the clinic.
The Numbers That Keep Founders Up at Night
Most preclinical failures aren’t caused by bad science. They’re caused by strategic gaps, execution missteps, and misallocated runway.
public biotechs with <12 months of cash (2024)
biotech seed-to-Series A in <24 months
of clinical holds are in cell and gene therapy trials
Sources: EY Beyond Borders Biotechnology Report 2025 (cash reserves)|StepStone (Carta data): seed-to-Series A graduation rates|Pietrusko et al. (PMC): clinical holds in cell and gene therapy
The difference between the teams that make it and the teams that stall is not always the quality of the science. It is the quality of the strategy, the precision of the execution, and whether someone on the team has seen what happens when an investor or acquirer opens your data package.
From Unmet Need to Diligence-Ready
A clear path from first conversation to a development plan that survives scrutiny.
Strategy Call
Tell us about your program, your stage, and what’s keeping you up at night. Complimentary, 30 minutes, no obligation.
Strategy Diagnostic
A focused assessment that identifies your critical gaps, risks, and near-term priorities. 100% of the diagnostic fee applies as credit toward your Preclinical Roadmap.
Preclinical Roadmap
Your diligence-ready development plan: study-by-study sequencing from discovery through IND-enabling, with timelines, budgets, CRO strategy, and biomarker planning.
Recommended Engagements by Stage
Every company is different. Here are the engagements that tend to deliver the most value at each stage.
First CRO study approaching · Need to prove feasibility · Board wants a plan
Strategy Diagnostic
Your entry point: a multidimensional program assessment with gap analysis, risk summary, and prioritized next steps. 100% credit toward your Preclinical Roadmap.
Study Design Review
Independent protocol review before committing. Covers model, design, endpoints, controls, and regulatory alignment.
Building toward IND-enabling · Need to sequence spend against value inflection · Series B or partnership is the target
Preclinical Roadmap
Our signature engagement: a diligence-ready, study-by-study plan from discovery through IND-enabling with timelines, CRO shortlists, budgets, and biomarker strategy.
Portfolio Assessment
Prioritize programs, build a next-study plan for each, and create the board narrative.
Diligence Readiness
Complete preclinical story with mock diligence, Q&A guide, and gap analysis.
Advisory / Fractional
Ongoing strategic guidance or embedded fractional leadership as you execute.
Executing IND-enabling studies · Need senior nonclinical leadership · Preparing for partner discussions
Pre-IND and IND Writing
Pre-IND strategy, briefing document sections, anticipated FDA questions. Module 2.4, 2.6, study report summaries.
Partner Readiness
Preclinical data package for partner review with competitive positioning and mock BD diligence.
Fractional Head of Preclinical Strategy
Embedded senior leadership for your preclinical program: CRO oversight, study design, board materials, risk register, and milestone governance.
In the clinic · Nonclinical studies needed to support clinical program · Label expansion or new indication
Nonclinical Support for Clinical Programs
Study design and oversight for nonclinical studies that support ongoing clinical efforts: additional tox, biodistribution, new ROAs, or label expansion.
IND Amendment and Supplement Writing
Nonclinical sections for IND amendments, annual reports, and regulatory submissions as programs evolve.
Fractional Nonclinical Leadership
Embedded part-time nonclinical lead: CRO oversight, study design, regulatory writing, and cross-functional alignment with clinical operations.
Why Founders Choose BridgeLine
Every engagement is designed to protect your runway and improve the quality of your next decision.
Satisfaction Guarantee
If a diagnostic doesn’t deliver at least 3 actionable recommendations, we refund the full fee. Clear scope and pricing before you commit.
100% Diagnostic Credit Toward Your Roadmap
Every Strategy Diagnostic fee applies as 100% credit toward your Preclinical Roadmap within 9 months. Your diagnostic is a down payment, not a sunk cost.
Presentation-Ready Output
Every deliverable is formatted for board meetings and investor presentations. Visual timelines, budget tables, and executive summaries.
The Acquirer’s Lens
We’ve sat on both sides of the table, building programs toward IND and evaluating them through scientific diligence for licensing and acquisition.
Ready to Talk About Your Program?
Book a complimentary Strategy Call. We’ll discuss your situation and recommend the right engagement.
Book a Strategy Call30-minute call · No obligation · Confidential
info@bridgelinetranslational.com · bridgelinetranslational.com